Anthony Hall

Dr Anthony Hall graduated from King’s College London with first class joint honours in physiology and pharmacology before going on to study medicine at the Royal Free Hospital. He has over 25 years of drug development with ten years working on rare diseases.

As CMO at Healx Tony will be responsible for progressing the company’s rare disease drug candidates through the clinic. He will also oversee relationships with regulatory bodies at a global level.

Prior to joining Healx, Tony worked as CMO at Aparito and as Therapeutic Area Head of Orphan Drugs at Mereo BioPharma. He previously co-designed the development programme for DevelopAKUre, an FP7-funded project to repurpose nitisinone for the treatment of the rare metabolic disease, alkaptonuria (AKU). He is currently Trustee of Findacure and a member of the Scientific Advisory Board at the patient group charity Duchenne UK. He is also co-editor of The Patient Group Handbook for rare diseases.